2. UroToday Home
  3. Trials in Progress

Trials in Progress

Randomized Phase II Stereotactic Ablative Radiation Therapy for Metastatic Unresected Renal Cell Carcinoma Receiving Immunotherapy (SAMURAI)

Trials in Progress
Videos

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

  • Condition: Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
  • Study ID: NCT05327686
View Trial
Conference Coverage
Conference Highlights Written by Physician Scientists
Presented by Rana McKay, MD
(UroToday.com) The 2023 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between June 2nd and June 6th was host to a kidney and bladder cancers poster session. Dr. Rana McKay presented the rationale and study framework for SAMURAI, a randomized phase II trial evaluating stereotactic ablative radiation therapy (SABR) for patients with metastatic, unresected renal cell carcinoma (RCC) receiving systemic immunotherapy.